Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 16Prostatic Neoplasms 10Clear-cell metastatic renal cell carcinoma 7Urinary Bladder Neoplasms 3Urethral Neoplasms 3Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Seminoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Penile Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vulvar Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Teratoma, Testicular 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × CTLA-4 Antigen × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡